Plain-English translation of NCT05822193 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are trying to understand how many people in Brazil experience long-term health problems after COVID-19, what those problems are, and which people are most at risk. This is an important question because many people have ongoing symptoms weeks or months after their initial infection, and doctors need better information to help them.
Many people continue to experience symptoms like fatigue, breathing problems, and brain fog long after COVID-19, but we don't know how common this is in Brazil or what factors make someone more likely to develop these long-term effects. This study will help doctors and public health leaders understand the real impact on people's lives and plan better care.
You likely qualify if…
You likely don't qualify if…
You will participate remotely from home through online or phone appointments. Researchers will ask you questions about your COVID-19 illness, any ongoing symptoms you may be experiencing, and how these symptoms affect your daily life, work, and overall quality of life. The study is looking back at what happened after your COVID-19 infection, so there is no new medication or treatment involved — just sharing your story to help researchers learn.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Brazil
Sponsor
Inova Medical
Collaborators
Merck Sharp & Dohme LLC
Enrollment target
~1,694 participants
Started
July 2023
Primary completion
July 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Maicon Falavigna, MD, PhD
Inova Medical
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.